Jones Financial Companies
JSPR icon

Jones Financial Companies’s Jasper Therapeutics JSPR Stock Holding History

Jones Financial Companies’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Hold
50
– – ﹤0.01% 4928
2026
Q1 		$53 Hold
50
– – ﹤0.01% 4669
2025
Q4 		$92 Hold
50
– – ﹤0.01% 4321
2025
Q3 		$124 Buy
+50
New +$152 ﹤0.01% 4151

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jones Financial Companies's JSPR Position: Q2 2026 in Review

Jones Financial Companies held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 50 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #4928.

Jones Financial Companies first reported a position in JSPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $124 in Q3 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Jones Financial Companies held 50 shares of Jasper Therapeutics worth $17 as of Q2 2026.
  • Jones Financial Companies left its Jasper Therapeutics share count unchanged in Q2 2026.
  • Jasper Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4928 holding.
  • Jones Financial Companies first reported a position in Jasper Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Jones Financial Companies's Jasper Therapeutics position peaked at $124 in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.